GSK2110183 hydrochloride

• CAT Number: I005868
• CAS Number: 2070009-64-0
• Molecular Formula: C18H17Cl3F2N4OS
• Molecular Weight: 481.77
• Purity: ≥95%
• Target: Akt
• Solubility: DMSO: ≥ 36 mg/mL
• Storage: Store at -20°C
• IC50: 0.08/2/2.6 nM(Akt1/Akt2/Akt3)
• IUPAC Name: N-[(2S)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)thiophene-2-carboxamide;hydrochloride
• InChI: InChI=1S/C18H16Cl2F2N4OS.ClH/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9;/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27);1H/t10-;/m0./s1
• InChIKey: BCVQLTLODHPIJM-PPHPATTJSA-N
• SMILES: CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)N[C@@H](CC3=CC(=C(C=C3)F)F)CN)Cl.Cl

GSK2110183 hydrochloride（Cat No.:I005868）is a selective inhibitor of the enzyme Akt (also known as Protein Kinase B), which plays a key role in cell survival, growth, and metabolism. By inhibiting Akt, GSK2110183 disrupts the signaling pathways that promote cancer cell growth and survival, making it a potential therapeutic agent for cancer treatment. It has been investigated for its efficacy in treating various cancers, particularly those with aberrant Akt activation, such as breast, lung, and pancreatic cancers. Ongoing clinical trials are exploring its safety, pharmacokinetics, and effectiveness as a targeted cancer therapy.

Reference

[1]. Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One. 2014 Jun 30;9(6):e100880.